Utilization of MHC class I transgenic mice for development of minigene DNA vaccines encoding multiple HLA-restricted CTL epitopes - PubMed (original) (raw)
. 1999 Apr 1;162(7):3915-25.
J Fikes, G Hermanson, B Livingston, C Crimi, M Qin, M F del Guercio, C Oseroff, C Dahlberg, J Alexander, R W Chesnut, A Sette
Affiliations
- PMID: 10201910
Utilization of MHC class I transgenic mice for development of minigene DNA vaccines encoding multiple HLA-restricted CTL epitopes
G Y Ishioka et al. J Immunol. 1999.
Abstract
We engineered a multiepitope DNA minigene encoding nine dominant HLA-A2.1- and A11-restricted epitopes from the polymerase, envelope, and core proteins of hepatitis B virus and HIV, together with the PADRE (pan-DR epitope) universal Th cell epitope and an endoplasmic reticulum-translocating signal sequence. Immunization of HLA transgenic mice with this construct resulted in: 1) simultaneous CTL induction against all nine CTL epitopes despite their varying MHC binding affinities; 2) CTL responses that were equivalent in magnitude to those induced against a lipopeptide known be immunogenic in humans; 3) induction of memory CTLs up to 4 mo after a single DNA injection; 4) higher epitope-specific CTL responses than immunization with DNA encoding whole protein; and 5) a correlation between the immunogenicity of DNA-encoded epitopes in vivo and the in vitro responses of specific CTL lines against minigene DNA-transfected target cells. Examination of potential variables in minigene construct design revealed that removal of the PADRE Th cell epitope or the signal sequence, and changing the position of selected epitopes, affected the magnitude and frequency of CTL responses. Our results demonstrate the simultaneous induction of broad CTL responses in vivo against multiple dominant HLA-restricted epitopes using a minigene DNA vaccine and underline the utility of HLA transgenic mice in development and optimization of vaccine constructs for human use.
Similar articles
- Human immunodeficiency virus type 1 Nef epitopes recognized in HLA-A2 transgenic mice in response to DNA and peptide immunization.
Sandberg JK, Leandersson AC, Devito C, Kohleisen B, Erfle V, Achour A, Levi M, Schwartz S, Kärre K, Wahren B, Hinkula J. Sandberg JK, et al. Virology. 2000 Jul 20;273(1):112-9. doi: 10.1006/viro.2000.0360. Virology. 2000. PMID: 10891413 - A novel HBV DNA vaccine based on T cell epitopes and its potential therapeutic effect in HBV transgenic mice.
Li X, Yang X, Jiang Y, Liu J. Li X, et al. Int Immunol. 2005 Oct;17(10):1293-302. doi: 10.1093/intimm/dxh305. Epub 2005 Aug 19. Int Immunol. 2005. PMID: 16113237 - Endoplasmic reticulum targeting sequence enhances HBV-specific cytotoxic T lymphocytes induced by a CTL epitope-based DNA vaccine.
Xu W, Chu Y, Zhang R, Xu H, Wang Y, Xiong S. Xu W, et al. Virology. 2005 Apr 10;334(2):255-63. doi: 10.1016/j.virol.2005.01.040. Virology. 2005. PMID: 15780875 - Immunodominance across HLA polymorphism: implications for cancer immunotherapy.
Kim CJ, Parkinson DR, Marincola F. Kim CJ, et al. J Immunother. 1998 Jan;21(1):1-16. J Immunother. 1998. PMID: 9456431 Review. - HLA class I binding regions of HIV-1 proteins.
Choppin J, Guillet JG, Lévy JP. Choppin J, et al. Crit Rev Immunol. 1992;12(1-2):1-16. Crit Rev Immunol. 1992. PMID: 1384546 Review.
Cited by
- DNA and modified vaccinia virus Ankara vaccines encoding multiple cytotoxic and helper T-lymphocyte epitopes of human immunodeficiency virus type 1 (HIV-1) are safe but weakly immunogenic in HIV-1-uninfected, vaccinia virus-naive adults.
Gorse GJ, Newman MJ, deCamp A, Hay CM, De Rosa SC, Noonan E, Livingston BD, Fuchs JD, Kalams SA, Cassis-Ghavami FL; NIAID HIV Vaccine Trials Network. Gorse GJ, et al. Clin Vaccine Immunol. 2012 May;19(5):649-58. doi: 10.1128/CVI.00038-12. Epub 2012 Mar 7. Clin Vaccine Immunol. 2012. PMID: 22398243 Free PMC article. Clinical Trial. - Development of an oral DNA vaccine against MG7-Ag of gastric cancer using attenuated salmonella typhimurium as carrier.
Guo CC, Ding J, Pan BR, Yu ZC, Han QL, Meng FP, Liu N, Fan DM. Guo CC, et al. World J Gastroenterol. 2003 Jun;9(6):1191-5. doi: 10.3748/wjg.v9.i6.1191. World J Gastroenterol. 2003. PMID: 12800222 Free PMC article. - Advancing our understanding of HIV co-infections and neurological disease using the humanized mouse.
Endsley JJ, Huante MB, Naqvi KF, Gelman BB, Endsley MA. Endsley JJ, et al. Retrovirology. 2021 Jun 16;18(1):14. doi: 10.1186/s12977-021-00559-z. Retrovirology. 2021. PMID: 34134725 Free PMC article. Review. - Structural features of peptide analogs of human histocompatibility leukocyte antigen class I epitopes that are more potent and immunogenic than wild-type peptide.
Tangri S, Ishioka GY, Huang X, Sidney J, Southwood S, Fikes J, Sette A. Tangri S, et al. J Exp Med. 2001 Sep 17;194(6):833-46. doi: 10.1084/jem.194.6.833. J Exp Med. 2001. PMID: 11560998 Free PMC article. - Identification of T. gondii epitopes, adjuvants, and host genetic factors that influence protection of mice and humans.
Tan TG, Mui E, Cong H, Witola WH, Montpetit A, Muench SP, Sidney J, Alexander J, Sette A, Grigg ME, Maewal A, McLeod R. Tan TG, et al. Vaccine. 2010 May 21;28(23):3977-89. doi: 10.1016/j.vaccine.2010.03.028. Epub 2010 Mar 26. Vaccine. 2010. PMID: 20347630 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Other Literature Sources
Molecular Biology Databases
Research Materials